GlassScriptPhysician profile
Craig A Snyder
NPI 1427008945
$3,142.05
in general payments reported to CMS, 2019-2025
30 companies · $1,139 in 2025
The $1,139 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $155 · 2021: $144 · 2022: $509 · 2023: $320 · 2024: $551 · 2025: $1,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,010.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $676.22 | 2019-2025 | Wolverine Coronary Cutting Balloon, Guidezilla, Comet |
| Abbott Laboratories | $269.83 | 2022-2024 | Coroflow, Cardiomems, Xience Skypoint |
| E.R. Squibb & Sons, L.L.C. | $243.03 | 2019-2024 | Eliquis, Camzyos |
| Heartflow, INC. | $211.54 | 2024-2025 | |
| Novo Nordisk INC | $194.67 | 2022-2025 | Wegovy, Ozempic |
| Pfizer INC. | $167.75 | 2019-2025 | |
| Abiomed | $163.49 | 2019-2025 | Impella |
| Cvrx, INC. | $144.40 | 2021-2025 | Barostim Neo System |
| Atricure, INC. | $131.15 | 2024-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Sanofi-Aventis U.S. LLC | $107.95 | 2019-2024 | |
| Amgen INC. | $93.82 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.15 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $90.49 | 2019-2023 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $87.32 | 2021-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $82.91 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $78.49 | 2019-2025 | |
| Amarin Pharma, INC. | $69.95 | 2019-2022 | |
| Shockwave Medical, INC | $32.34 | 2025 | |
| Biosense Webster, INC. | $30.20 | 2020 | |
| Medtronic, INC. | $27.39 | 2025 | Ffrangio |
| Imperative Care, INC | $23.72 | 2025 | Symphony Catheter |
| Daiichi Sankyo INC. | $16.15 | 2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $15.00 | 2022 | |
| Currax Pharmaceuticals LLC | $14.72 | 2022 | |
| Azurity Pharmaceuticals, INC. | $14.55 | 2024 | Edarbyclor |
| Itamar Medical INC | $14.18 | 2024 | Watchpatone |
| Sanofi Pasteur INC. | $13.77 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $12.80 | 2019 | |
| Merck Sharp & Dohme LLC | $11.57 | 2019 | |
| Gilead Sciences, INC. | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.